drugset
drugset / Trial / NCT05382767

Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity

NCT05382767 ↗

Phase 1 Completed 24 enrolled CKD Bio Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

Multicenter, randomized, double-blind, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501A in Subjects with Post-stroke Upper Limb Spasticity

Timeline

Start
2022-06-02
Primary completion
2022-12-08
Completion
2022-12-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic — —
Subject CKDB-501A Protein / enzyme biologic — —

Indications

diplegia of upper limb